Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the FDA-approved subcutaneous isatuximab delivery. Although ...

Patients in the US are to have easier initial access to a new drug to treat Alzheimer’s disease thanks to a decision by the US Food and Drug Administration (FDA). Clinical trials have shown that the ...

Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte to evaluate additional subcutaneous ...

With concerns over the competitiveness of its subcutaneous (SC) injection platform leading to a sharp decline in its stock ...

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option ...

A new advanced body composition scan measures muscle, fat, and dangerous visceral fat, helping patients track health beyond the number on the scale.

Temporary Suspension of KOSPI Transfer Listing...Background of Staying Attracts Attention While Alteogen has faced share ...

All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -- Independent ...

People living with early Alzheimer’s disease can now begin treatment with Leqembi without setting foot in an infusion center.

A real world study suggests found that more than three-quarters of participants receiving the anti-amyloid drug Leqembi ...

The results of two phase 3 trials suggest that investigational drug bepirovirsen reduces HBsAg production, helping the immune ...

All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety ...